Arcellx Inc【ACLX】株式ニュース

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights

-- Recently released ASH abstracts for the company’s Phase 1 and iMMagine-1 studies investigating anito-cel in relapsed or refractory multiple...

Form 8-K - Current report

Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study

-- 30.2-month median progression-free survival with a median follow-up of 38.1 months in the Phase 1 study of anito-cel; median overall survival...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

ACLX new 52 week high

ACLX new 52 week high

👍️0

Monksdream 10月前

ACLX new 52 week high

👍️0

Monksdream 10月前

ACLX new 52 week high

👍️0

bandit007 2年前

Going beast mode into next week.

👍️0

TheyWantYourShares 3年前

Nice correction coming here. New IPO at 16… company is flush with capital/cash. Moves coming and getting in now will pay off big IMHO.

Got in on the drop @average: 13.12 … 2 and 3 days ago.

$ACLX

GLTA!!

-TWYS

👍️0

crudeoil24 3年前

Net loss of $44M > no revenues! ( over 9 month period)

ACLX

👍️0

crudeoil24 3年前

Arcellx Inc. ACLX, has set terms for its initial public offering, in which the Maryland-based biotechnology company, which is developing cancer treatments, looks to raise up to $140.25 million. The company said it is offering 8.25 million shares in the IPO, which is expected to price between $15 and $17 a share. With 33.54 million shares expected to be outstanding after the IPO, the expected pricing could value the company at up to $570.24 million. The stock is expected to list on the Nasdaq under the ticker symbol "ACLX." BofA Securities, SVB Leerink, Barclays and William Blair are the lead underwriters. The company recorded a net loss of $44.30 million on no revenue during the nine months ended Sept. 30, after a loss of $23.00 million on no revenue in the same period a year ago. Arcellx is looking to go public at a time of relative investor disdain for IPOs and biotechs, as the Renaissance IPO ETF IPO, -3.27% has plunged 37.2% over the past three months and the iShares Biotechnology ETF IBB, -1.39% has tumbled 19.8%, while the S&P 500 SPX, +0.31% has slipped 3.8%.

👍️0

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Arcellx Inc (ACLX)

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

ACLX ニュース

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights

Form 8-K - Current report

Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

ACLX Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Arcellx Inc (ACLX) ニュース

Arcellx Inc (ACLX)

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

ACLX ニュース

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights

Form 8-K - Current report

Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

ACLX Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手